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DIAGNOSIS OF
HYPERTROPHIC
CARDIOMYOPATHY
To the Editor:
With interest, we read the recent
guideline for hypertrophic cardiomy-
opathy (HCM) and highly appreciate
the useful clinical information.1
HCM is a pathophysiologically het-
erogeneous condition. We agree with
the authors that there is comprehen-
sive evidence that mutations in 8
genes encoding proteins of, or associ-
ated with, the sarcomere can cause
HCM. These are, as stated in chapter
6 of the guideline, the genes encoding
b myosin heavy chain, myosin bind-
ing protein C, troponin T, troponin I,
a-tropomyosin, actin, regulatory light
chain, and essential light chain. How-
ever, only about 40% to 60% of HCM
cases can be attributed to these 8
genes.2,3
More recently, a ninth gene was
convincingly linked to HCM after
a genome-wide linkage analysis. Mu-
tations in CSRP3 encoding muscle
LIM protein were shown to co-
segregate with HCM in several fami-
lies in whom gene mutations in the 8
incriminated sarcomeric proteins had
been previously excluded.4 All these
mutations affected highly conserved
residues and were not found in the
control genomes. Linkage analysis
with a highly significant 5.9 logarithm
of the odds score in a single large
family provided additional genetic ev-
idence. Physicians and geneticists un-
aware of the mutation status ensured
an unbiased attribution of disease1234 The Journal of Thoracic andstatus and an unbiased genome-wide
linkage analysis in that family.5 Fur-
thermore, functional data supported
the genetic results. Cardiomyocyte
disarray was observed in CSRP3
mutation-positive cardiac tissue from
patients with HCM. The findings indi-
cate that CSRP3 mutations cause
‘‘true’’ HCM and not merely a HCM
phenocopy.
Although CSRP3 mutations in pa-
tients with HCM are not common
(<5%), we believe that there is con-
vincing, scientific evidence that the
gene should be included in the list of
confirmed HCM disease genes.
TPM1 and ACTC (encoding a-tropo-
myosin and actin) mutations occur at
a frequency not much different than
CSRP3 mutations. The prevalence of
HCM disease genes is also related to
ethnicity. Such patterns require active
surveillance of disease genes and
CSRP3 should be included. To learn
more about the ethnic spectrum of
disease genes and specific founder
mutations we propose including all
well-established disease genes into
scientific genetic screening analyses.
Muscle LIM protein is not confined
solely to sarcomeric localizations but
can be localized to the sarcolemma
and to the cell nucleus. Mechanisti-
cally, there is much to be learned
about this protein, its gene, and their
contributions to HCM. We therefore
wish to draw attention to CSRP3.
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STRATEGY FOR REMOVING
RETROPERITONEALTUMORS
WITH EXTENSIVE
CAVOATRIAL INVOLVEMENT
To the Editor:
The authors compare beating
heart cardiopulmonary bypass (CPB)
and hypothermic circulatory arrest
(HCA) for removing retroperitoneal
tumors with extensive cavoatrial in-
volvement.1 They included in their se-
ries retroperitoneal renal tumors with
level III-IV tumor thrombus
Letters to the Editorextension; 56 (39%) and 88 (61%)
underwent CPB and HCA, respec-
tively. Since 1997, we have used liver
transplant techniques for mobilization
of the liver off the inferior vena cava
(piggyback mobilization) to aid in
the resection of renal cell carcinoma
with level III tumor thrombus.2 None
of the patients required a thoracoabdo-
minal approach, CBP, HCA or veno-
venous bypass. Just recently, we
published our technique step by step
for treating renal cell carcinoma with
tumor thrombus, extending our expe-
rience to 56 patients with level III
and 12 with level IV tumor thrombus,
and only 3 patients with level IV re-
quired CPB.3 This experience has
now been extended to 70 patients
with level III thrombus. We also re-
ported our experience removing an
adherent4 and nonadherent5 level IV
(intra-atrial thrombus) tumorNotices of Correction
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approach, median sternotomy, or
CPB. It is important to describe other
experiences of treating renal cell car-
cinoma with level III-IV cavoatrial in-
volvement in which CPB or HCA can
be avoided for most cases, thereby
simplifying the operation even more.
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